* DRUGS CHIEF SAYS EROSION IN EUROPEAN RITUXAN SALES TO INTENSIFY IN 2018 AS BIOSIMILARS ENTER MORE MARKETS AFTER 26 PERCENT 4TH QUARTER DROP Source text for Eikon: Further company coverage: (Reporting by John Miller)